Friday, July 10, 2026

biotech · Advanced Solid Tumors · Tumor, Solid · EIKN

Eikon Therapeutics

Eikon Therapeutics is a biotech organization headquartered in Millbrae, USA. It trades on NYSE under ticker EIKN. Primary therapeutic focus areas include Advanced Solid Tumors, Tumor, Solid, Advanced Melanoma, Advanced s

230 Harriet Tubman Way, Millbrae, CA 94030, US HQ
2019 Founded
404 Employees
Public company Type
EIKN · NYSE Ticker
Company details
Status
Public
HQ
230 Harriet Tubman Way, Millbrae, CA 94030, US
Founded
2019
Employees
404
Programs
15
Drugs
13
Patents
4
Clinical program

BDB001 (EIK1001)

Phase 1 · small molecule · Tumor, Solid

BDB001 (EIK1001) for Tumor, Solid is a Phase 1 program (small_molecule) at Eikon Therapeutics with 2 ClinicalTrials.gov record(s).

← All Eikon Therapeutics projects Phase 1 small molecule completed

Internal code BDB001-101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Eikon Therapeutics
Phase
Phase 1
Modality
small_molecule
Indication
Tumor, Solid
Status
completed
Trials
2

Clinical trials